The Other Ventricle With Left Ventricular Assist Devices

Lynne Warner Stevenson, MD; Jordan R.H. Hoffman, MD; Jonathan N. Menachem, MD


J Am Coll Cardiol. 2022;78(23) 

In This Article

Impact of RHF Beyond 3 Months

This analysis enabled precise associations between adverse events and RHF during LVAD support. Stroke and gastrointestinal bleeding were higher with RHF. Glomerular filtration rate declined in all patients between 3 and 12 months, with lower absolute values in the RHF patients before and after LVAD; the relationship is confounded, however, because renal dysfunction is also one of the clinical criteria to define RHF. Generally good after LVAD, quality of life was worse with RHF. Adverse events have consistently been associated with worse survival after LVAD,[7] as confirmed here. RHF at 1–3 months conferred higher 1-year mortality, 28.1% with moderate and 16.7% with mild RHF, compared with 6.9% without RHF. Other studies have shown that the adverse impact of RHF on outcomes after LVADs persists even after transplantation.[8]